11 pharmaceutical companies reported mixed results in the second quarter of 2019

[pharmaceutical network industry trends] more than half of 2019 has passed At present, many pharmaceutical companies have published the second quarter of 2019 financial statements According to the situation of the drug companies that have been publicized, the overall performance is mixed On August 7, CUDA pharmaceutical announced its financial report, which showed that the company's net profit attributable to ordinary shareholders in the second fiscal quarter of 2019 was - 656000 US dollars, an increase of 85.41% year on year, and its operating revenue was 10.7910 million US dollars, an increase of 22.99% year on year According to the public information, the company is a biotechnology company focusing on a novel drug for the treatment of liver diseases and its development and commercialization On August 7, denavir announced its financial report, which showed that the company's net profit attributable to ordinary shareholders in the second quarter of fiscal year 2019 was - 42.7130 million US dollars, down 8.29% year on year; its operating revenue was 8.3010 million US dollars, up 561.96% year on year According to the public information, denavir is a fully integrated biopharmaceutical company that focuses on utilizing the power of innate and adaptive immune responses through toll like receptor ("TLR") stimulation On August 7, amag pharmaceutical released its financial report, which showed that the company's net profit attributable to ordinary shareholders in the second quarter of fiscal year 2019 was - 121 million US dollars, down 501.7% year on year; its operating revenue was 78.1099 million US dollars, down 46.59% year on year According to the public information, amag pharmaceutical is a professional pharmaceutical company, which produces ferraheme (nano iron oxide) drugs, intravenous injection (IV) for the treatment of iron deficiency anemia (IDA) and adult chronic kidney disease (CKD); mugard oral wound washing mucosal adhesive drugs for the treatment of oral mucositis Kala pharmaceutical released its financial report on August 6, which showed that the company's net profit attributable to ordinary shareholders in the second quarter of fiscal year 2019 was - 23.825 million US dollars, down 62.96% year-on-year, and its operating revenue was 2.057 million US dollars According to the public information, Kala Pharmaceutical Co., Ltd is a biopharmaceutical company, focusing on the development and commercialization of its proprietary nanoparticles based colloidal osmotic particles or MPP technology, with its initial focus on the treatment of eye diseases Clovis oncology medicine on August 2, Clovis oncology Medicine released its financial report, which showed that the company's net profit attributable to ordinary shareholders in the second fiscal quarter of 2019 was - 120 million US dollars, down 19.01% year-on-year; its operating revenue was 32.978 million US dollars, up 38.81% year-on-year According to public information, the company is a biopharmaceutical company, focusing on the acquisition, development and commercialization of innovative anti-cancer drugs in the international market The company intends to continue to obtain licenses or rights to develop tumor compounds at all stages of clinical development On August 2, deciphera pharmaceutical released its financial report, which showed that the company's net profit attributable to ordinary shareholders in the second fiscal quarter of 2019 was - 21.46 million US dollars, an increase of 1.06% year-on-year, and its operating revenue was 25 million US dollars According to public information, deciphera pharmaceutical is a clinical stage biopharmaceutical company, which is mainly engaged in the development of new drugs to improve the lives of cancer patients On August 1, blueprint pharmaceutical released its financial report, which showed that the company's net profit attributable to ordinary shareholders in the second fiscal quarter of 2019 was - 99.6810 million US dollars, down 268.53% year on year; its operating revenue was 5.11 million US dollars, down 87.67% year on year According to the public information, blueprint medicine is a biopharmaceutical company focusing on improving the life of patients' abnormal activated protein kinase genome driven disease definition On August 1, Syros pharmaceutical released its financial report, which showed that the company's net profit attributable to ordinary shareholders in the second fiscal quarter of 2019 was - 1945.5 million US dollars, down 38.5% year on year; its operating revenue was 462000 US dollars, up 23.2% year on year According to public information, Syros Pharma is a biopharmaceutical company that has pioneered the understanding of genes that control activation and suppression of genomic regions On August 1, the company released its financial report, which showed that the company's net profit attributable to ordinary shareholders in the second fiscal quarter of 2019 was - 23.018 million US dollars, an increase of 33.68% year-on-year; its operating revenue was 9.682 million US dollars, a decrease of 29.6% year-on-year According to the public information, Ricon pharmaceutical is a biopharmaceutical company that focuses on the research and Realization of breakthroughs in the treatment of human diseases On July 30, unlimited pharmaceutical released its financial report, which showed that the company's net profit attributable to ordinary shareholders in the second quarter of fiscal year 2019 was - 10.514 million US dollars, a year-on-year decrease of 51%; its operating revenue was 257000 US dollars According to the public information, infinite pharmaceutical is an innovative drug R & D company, which aims to develop and provide drugs for patients to treat diseases that do not meet the treatment requirements of patients On July 30, Ironwood pharmaceutical released its financial report, which showed that the company's net profit attributable to ordinary shareholders in the second quarter of fiscal year 2019 was 12.283 million US dollars, an increase of 124.87% year-on-year; its operating revenue was 102 million US dollars, an increase of 26.03% year-on-year According to public information, Ironwood pharmaceutical is a start-up pharmaceutical company dedicated to exploring, developing and promoting drugs to improve the lives of patients.